Fermenta Biotech Ltd
₹ 320
0.99%
04 Jun
- close price
About
Incorporated in 1951, Fermenta Biotech
Ltd manufactures Active Pharmaceutical Ingredient, Aqua CHL, Biotechnology and Nutraceutical products[1]
Key Points
- Market Cap ₹ 941 Cr.
- Current Price ₹ 320
- High / Low ₹ 399 / 249
- Stock P/E 14.1
- Book Value ₹ 138
- Dividend Yield 0.78 %
- ROCE 20.4 %
- ROE 17.4 %
- Face Value ₹ 5.00
Pros
Cons
- The company has delivered a poor sales growth of 6.94% over past five years.
- Company has a low return on equity of 12.9% over last 3 years.
- Working capital days have increased from 48.5 days to 95.8 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare
Loading peers table ...
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 142 | 155 | 164 | 302 | 403 | 292 | 376 | 397 | 349 | 335 | 468 | 525 | |
| 126 | 134 | 152 | 209 | 248 | 225 | 293 | 335 | 330 | 307 | 352 | 426 | |
| Operating Profit | 16 | 21 | 12 | 93 | 156 | 66 | 83 | 62 | 18 | 28 | 115 | 100 |
| OPM % | 11% | 13% | 7% | 31% | 39% | 23% | 22% | 16% | 5% | 8% | 25% | 19% |
| 0 | 1 | 3 | 9 | 6 | 12 | 8 | 8 | -20 | 4 | 7 | 29 | |
| Interest | 4 | 6 | 10 | 14 | 21 | 20 | 19 | 18 | 21 | 17 | 15 | 12 |
| Depreciation | 9 | 8 | 10 | 12 | 12 | 15 | 20 | 26 | 28 | 25 | 24 | 22 |
| Profit before tax | 3 | 7 | -6 | 76 | 129 | 43 | 52 | 27 | -51 | -10 | 83 | 96 |
| Tax % | 67% | 61% | 49% | 28% | 8% | -37% | 18% | 44% | 4% | 143% | 8% | 27% |
| 1 | 2 | -9 | 46 | 117 | 60 | 43 | 15 | -53 | -24 | 76 | 70 | |
| EPS in Rs | 0.17 | -0.41 | -4.14 | 12.21 | 42.71 | 20.23 | 15.46 | 5.25 | -17.36 | -7.84 | 26.12 | 24.39 |
| Dividend Payout % | 249% | -51% | -5% | 2% | 1% | 24% | 16% | 23% | -7% | -16% | 9% | 15% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 7% |
| 3 Years: | 15% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 52% |
| 5 Years: | 8% |
| 3 Years: | 67% |
| TTM: | -18% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 0% |
| 3 Years: | 32% |
| 1 Year: | 1% |
| Return on Equity | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 7% |
| 3 Years: | 13% |
| Last Year: | 17% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 5 | 14 | 14 | 14 | 14 | 14 | 15 | 14 |
| Reserves | 129 | 128 | 142 | 122 | 246 | 295 | 346 | 358 | 301 | 274 | 348 | 392 |
| 71 | 89 | 87 | 173 | 209 | 224 | 232 | 239 | 220 | 139 | 115 | 113 | |
| 60 | 70 | 75 | 87 | 92 | 80 | 94 | 96 | 102 | 120 | 137 | 128 | |
| Total Liabilities | 262 | 288 | 307 | 385 | 551 | 614 | 687 | 707 | 637 | 548 | 614 | 648 |
| 85 | 168 | 172 | 177 | 178 | 200 | 263 | 299 | 267 | 269 | 227 | 220 | |
| CWIP | 65 | 6 | 5 | 4 | 22 | 71 | 57 | 35 | 45 | 2 | 16 | 13 |
| Investments | 18 | 15 | 18 | 10 | 8 | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
| 94 | 99 | 112 | 193 | 344 | 342 | 367 | 373 | 321 | 277 | 372 | 414 | |
| Total Assets | 262 | 288 | 307 | 385 | 551 | 614 | 687 | 707 | 637 | 548 | 614 | 648 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15 | 4 | 2 | 59 | 90 | 34 | 63 | 43 | 116 | 105 | 41 | 93 | |
| -18 | -13 | 7 | -101 | -97 | -44 | -41 | -26 | -55 | -16 | -0 | -43 | |
| 1 | 10 | -12 | 89 | 12 | -47 | -1 | -22 | -41 | -91 | -51 | -42 | |
| Net Cash Flow | -2 | 1 | -4 | 47 | 6 | -57 | 21 | -4 | 19 | -1 | -10 | 8 |
| Free Cash Flow | -20 | -25 | -17 | 42 | 55 | -34 | 7 | 6 | 76 | 86 | 38 | 63 |
| CFO/OP | 119% | 35% | 35% | 83% | 79% | 73% | 92% | 85% | 610% | 370% | 38% | 109% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 91 | 101 | 99 | 83 | 59 | 87 | 66 | 80 | 44 | 76 | 74 | 78 |
| Inventory Days | 125 | 160 | 208 | 234 | 347 | 594 | 441 | 380 | 309 | 245 | 306 | 290 |
| Days Payable | 95 | 113 | 147 | 183 | 169 | 260 | 169 | 154 | 109 | 182 | 192 | 147 |
| Cash Conversion Cycle | 122 | 148 | 160 | 134 | 237 | 421 | 338 | 306 | 244 | 139 | 189 | 221 |
| Working Capital Days | -61 | -49 | 33 | 54 | 43 | 70 | 54 | 67 | -18 | 9 | 40 | 96 |
| ROCE % | 3% | 6% | 2% | 31% | 41% | 12% | 13% | 7% | -0% | 3% | 23% | 20% |
Insights
In beta| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| Asset Turnover Ratio (Annualized) x |
|
|||||||
| Global Presence (Number of Countries) Number |
||||||||
| Number of Global Customers Number |
||||||||
| Total R&D Expenditure INR Lakhs |
||||||||
| Total Employee Strength Number |
||||||||
| Hazardous Waste Generated (Efficiency Proxy) Metric Tonnes |
||||||||
| Number of Patents Granted (Annual) Number |
||||||||
| Animal Nutrition Segment Volume Growth (YoY) % |
||||||||
| Human Nutrition Segment Volume Growth (YoY) % |
||||||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Investor Presentation 28 May
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
27 May - Publication of audited financial results for the quarter and financial year ended March 31, 2026.
-
Corporate Action-Board approves Dividend
26 May - Board approved FY26 audited results, 74th AGM on August 11, and final dividend of Rs. 3.75 per share.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
26 May - Fermenta FY26 consolidated revenue Rs 547.8 crore, EBITDA Rs 122.2 crore, PAT Rs 70.3 crore; dividend Rs 3.75/share.
-
Intimation Under Regulation 30 And Other Applicable Provisions Of SEBI Listing Regulations
26 May - Board approved NSE direct listing application, 3,95,400 ESOPs, and subsidiary private placement plans.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
May 2026TranscriptAI SummaryPPT
-
Feb 2026TranscriptAI SummaryPPT
-
Nov 2025TranscriptAI SummaryPPT
-
Aug 2025TranscriptAI SummaryPPT
-
Jun 2025TranscriptAI SummaryPPT
-
Feb 2025TranscriptAI SummaryPPT
-
Nov 2024TranscriptAI SummaryPPT
-
Aug 2024TranscriptAI SummaryPPT
-
Jul 2024TranscriptAI SummaryPPT
-
Jun 2024TranscriptAI SummaryPPT
-
Jun 2024TranscriptAI SummaryPPT
-
Feb 2024TranscriptAI SummaryPPT
-
Nov 2023TranscriptAI SummaryPPT
-
Nov 2023TranscriptAI SummaryPPT
-
Sep 2023TranscriptAI SummaryPPT
-
Aug 2023TranscriptAI SummaryPPT
-
Jun 2023TranscriptAI SummaryPPT
-
Jun 2023TranscriptAI SummaryPPT
-
Feb 2023TranscriptAI SummaryPPT
-
Nov 2022TranscriptAI SummaryPPT
-
Sep 2022TranscriptAI SummaryPPT
-
Aug 2022TranscriptAI SummaryPPT
-
Jun 2022Transcript PPT
-
Jun 2022TranscriptAI SummaryPPT
-
May 2022TranscriptAI SummaryPPT
-
Mar 2022TranscriptAI SummaryPPT
-
Feb 2022Transcript PPT
-
Feb 2022TranscriptAI SummaryPPT
-
Dec 2021Transcript PPT
-
Nov 2021TranscriptAI SummaryPPT
-
Aug 2021Transcript PPT
-
Aug 2021TranscriptAI SummaryPPT
-
Jul 2021Transcript PPT
-
Jun 2021TranscriptAI SummaryPPT
-
Feb 2021Transcript PPT
-
Feb 2021TranscriptAI SummaryPPT
-
Dec 2020Transcript PPT
-
Nov 2020Transcript PPT
-
Sep 2020TranscriptAI SummaryPPT
-
Sep 2020TranscriptAI SummaryPPT
-
Jul 2020TranscriptAI SummaryPPT
-
Jun 2020TranscriptAI SummaryPPT
-
Jun 2020TranscriptAI SummaryPPT
-
Jun 2020TranscriptAI SummaryPPT
-
Feb 2020TranscriptAI SummaryPPT
-
Dec 2019TranscriptAI SummaryPPT
-
Nov 2019TranscriptAI SummaryPPT
-
Nov 2019TranscriptAI SummaryPPT
-
Aug 2019TranscriptAI SummaryPPT
-
May 2019TranscriptAI SummaryPPT
-
Feb 2019TranscriptAI SummaryPPT
-
Nov 2018TranscriptAI SummaryPPT
-
Nov 2018TranscriptAI SummaryPPT
-
Sep 2018TranscriptAI SummaryPPT
-
Aug 2018TranscriptAI SummaryPPT
Business Overview:[1][2]
a) FBL is engaged in development
and manufacturing of pharmaceuticals, biotechnology and environmental solutions used across various industries. It is a global player in manufacturing of Vitamin D3 in all its formats and has a non-China dependent supply chain.
b) Company is involved in manufacturing
of APIs for muscle relaxant and anti-flatulent applications. It delivers innovative enzymes used in manufacturing of active pharmaceutical ingredients and is involved in environmental solutions used for waste water treatment & management.
c) Also, company has strategic investments in subsidiaries / associate companies primarily dealing in manufacturing and marketing bulk drugs and providing services of sporting and health awareness activities / education activities.
d) Company also deals in lease rental business for ITES properties developed in Than